Bristol Myers Squibb has announced the presentation of more than 90 data disclosures, including 18 oral presentations, from its hematology and cell therapy research programs at the 66 th Annual Meeting and Exposition of the American Society of Hematology (ASH), to be held December 7-10 in San Diego, California.

These data highlight the next wave of innovative therapeutic approaches with the potential to transform patient outcomes in hematology and other disease areas explains the group.

' ''Our data at ASH reflect our unique ability to address unmet patient needs through our portfolio of leading cell therapies and the continued expansion of our work in targeted protein degradation,'' said Anne Kerber, senior vice president, head of late-stage clinical development, hematology, oncology and cell therapy (HOCT), Bristol Myers Squibb.

' This meeting gives us the opportunity to reinforce our commitment to this critical area of research and to highlight our ongoing efforts to transform the way hematological diseases are treated. '

Copyright (c) 2024 CercleFinance.com. All rights reserved.